Project Grant HT94252310689
Award Date
7/1/23
Completion Date
7/30/25
Dollars Obligated
$636K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
The University of Pittsburgh received a $6,699,872 Project Grant award on September 30, 2024 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "MICROGLIAL BREAKTHROUGHS IN LONGEVITY, AGING, AND SENESCENCE AFTER TBI (MICROBLAST)", will fund advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research will explore...
The University of Pittsburgh has been awarded a $602,986 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, effective August 1, 2024 through August 31, 2026, will fund a research project titled "A T CELL-GUIDED APPROACH TO DEVELOP ANTIGEN-SPECIFIC IMMUNOTHERAPIES FOR PEDIATRIC BRAIN TUMORS." This project aims to develop innovative immunotherapies for treating pediatric brain tumors by leveraging the...
The University of Pittsburgh - Of The Commonwealth System of Higher Education was awarded a $1,572,933.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, with a performance period from January 1, 2025 to December 31, 2028, will support research to explore "TARGETING LYSOSOMAL PATHWAYS TO IMPROVE HOST IMMUNITY POST CORONAVIRAL INFECTIONS". As a prominent research university with extensive...
The University of Pittsburgh - Of the Commonwealth System of Higher Education (University of Pittsburgh) was awarded a $1,246,455 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research to characterize a novel class of non-competitive androgen receptor antagonists from May 15, 2023 to May 14, 2026. The Military Medical Research and Development program aims to transform military and public health...
The University of Pittsburgh was awarded a $925,680 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2027 targeting the IGFBP2-SRC signaling axis to block metastatic spread and tumor-mesothelial crosstalk. Through this research, the University aims to develop medical solutions for the battlefield by investigating approaches to prevent cancer metastasis. The Military...
The University of Pittsburgh was awarded a $2,806,431.00 Project Grant on July 1, 2023 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to optimize small molecule therapeutics to treat focal segmental glomerulosclerosis. This basic, applied, and advanced biomedical research aims to transform health care by developing innovative and impactful medical solutions for Service Members and the American public. The University of Pittsburgh will...
The University of Pittsburgh was awarded a $1,005,056 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 through September 2025 to target MYCN in pediatric high-grade gliomas using combinatorial approaches. Through this award, the University of Pittsburgh will investigate medical solutions for childhood brain cancers affecting military families and the general...
The University of Pittsburgh received a $454,142.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "FERROPTOSIS AS A METABOLIC VULNERABILITY OF CYCLIN E-HIGH OVARIAN CANCER". This 2-year research project, with a performance period from May 2024 to May 2026, aims to investigate metabolic vulnerabilities in a specific type of ovarian cancer. The University of Pittsburgh is the primary...
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
The University of Pittsburgh - Of The Commonwealth System of Higher Education, doing business as The University of Pittsburgh, received a $724,997.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the project "RECOVERY OF TENDON INJURY BY TARGETING ITS ROOT CAUSE AND ENHANCING TENDON STEM CELLS." The grant period of performance is from July 1, 2023 to June 30, 2026. The project aims to conduct biomedical...